Navigation Links
Expert Panel Suggests PSA Test May Benefit Some Men
Date:7/17/2012

By Steven Reinberg
HealthDay Reporter

MONDAY, July 16 (HealthDay News) -- Men with a life expectancy of more than 10 years should talk with their doctor about getting a prostate-specific antigen (PSA) test for prostate cancer, an expert panel recommends.

The recommendation, from the American Society of Clinical Oncology (ASCO), is a response to recent guidance from the U.S. Preventive Services Task Force, which in May recommended against PSA screening for prostate cancer.

The ASCO panel recommends doctors discuss the benefits and risks of PSA testing with their symptom-less patients who have a life expectancy of more than 10 years. For men who would probably die earlier, the risks outweigh the benefits, the panel said.

"Men really need to go to their doctor and have a discussion of the risks and benefits of getting the PSA blood test," said panel co-chair Dr. Robert Nam, a uro-oncologist at the Odette Cancer Centre at the Sunnybrook Health Science Centre of the University of Toronto in Canada. "We felt from our review that doing the PSA blood test does save lives in certain groups of men. That's where we differ from the task force recommendation."

Nam's point was that men with serious medical problems such as other cancers, heart failure and chronic obstructive pulmonary disease will most likely die from those diseases long before they succumb to prostate cancer.

For these men, treatment and the side effects associated with treatment might be worse than any benefit, he noted.

Dr. Otis Brawley, chief medical officer for the American Cancer Society, said the new gudielines "are very similar to recommendations from the American Cancer Society and other groups, most of which leave room for screening within the individual physicianpatient relationship."

"PSA has been a victim of its own success," Nam said. The test's inability to distinguish prostate cancer from an enlarged prostate, called benign prostate hyperplasia, has led to too many unnecessary biopsies.

That's why a PSA test should be part of a diagnosis of prostate cancer, but the diagnosis should also include other risk factors, such as family history, Nam said.

The report was published in the July 16 online edition of the Journal of Clinical Oncology.

The panel's conclusions were based on a study that indicated PSA screening could reduce deaths from prostate cancer by 20 percent among a group of men with more than 10 years of life expectancy, even though it did not cut deaths in other men.

The panel could not agree on when PSA screening should start, Nam noted. However, he thinks 50 is a good time for most men to get their first PSA test. For men who have an increased risk, screening should start earlier, Nam added.

Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said "this is an attempt to educate men about the pluses and minuses of the PSA test, which is good."

PSA, however, is only one factor that can help men understand if they are at risk for prostate cancer, D'Amico noted.

"The other things that need to be discussed are whether they are at high risk for having high-grade prostate cancer -- the kind that kills you," D'Amico said.

These factors include being black or Hispanic, having an abnormal rectal exam or being older and having a family history of prostate cancer, he said.

The age factor is something that is often underestimated, D'Amico added. "The risk of prostate cancer increases with age," he explained.

And, older men are more likely to die from prostate cancer -- 50 percent of prostate cancer deaths are in men over 75, D'Amico said.

When men see their doctor they should discuss whether they are at risk for prostate cancer. If they are, then a PSA test should be considered. If they are at low risk, a PSA test might not be appropriate, he said.

More information

For more on prostate cancer, visit the American Cancer Society.

SOURCES: Robert Nam, M.D., uro-oncologist, Odette Cancer Centre, Sunnybrook Health Science Center, University of Toronto, Canada; Anthony D'Amico, M.D., Ph.D., chief, radiation oncology, Brigham and Women's Hospital, Boston; Otis Brawley, M.D., chief medical officer, American Cancer Society, July 16, 2012, Journal of Clinical Oncology, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experts from John Theurer Cancer Center to participate in the AAMDSIF Patient and Family Conference
2. Infant Formula Can Be a Major Source of BPA: Experts
3. Keep Infants Out of Sun and Heat, Experts Warn
4. Taxman Foundation pledges $2.5 million to boost training of digestive disease experts
5. Social Media Strategies and Solutions — Straight from the Experts
6. Dr. Edmund Lipskis & Dr. Lynn Lipskis Will be Featured On New National Television Show Entitled: “Leading The Field” World Class Experts Share Their Tips & Advice
7. Courts Verdict on Health-Care Reform Holds Surprises, Legal Experts Say
8. Greater L.A. Heating Up, Climate Experts Predict
9. DBT Expert Charles Swenson to Present at Upcoming Clearview Workshop
10. Vision Therapy Expert Announces Vision Therapy Best Treatment for Amblyopia
11. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Expert Panel Suggests PSA Test May Benefit Some Men
(Date:4/26/2017)... ... , ... Journal of Oral Implantology – Tooth loss is not ... health, including complications with speech, eating, and overcompensation of mouth due to the deficiency. ... As the number of tooth replacements increase, it is imperative to design an implant ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, ... cells) Phase I/II HOPE clinical trial in Duchenne announced today. , Coalition ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: